# MK-3475 in Melanoma and NSCLC Patients With Brain Metastases

> **NCT02085070** · PHASE2 · COMPLETED · sponsor: **Yale University** · enrollment: 65 (actual)

## Conditions studied

- Melanoma
- Non-Small Cell Lung Cancer
- Brain Metastases

## Interventions

- **DRUG:** MK-3475

## Key facts

- **NCT ID:** NCT02085070
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2020-02-27
- **Final completion:** 2020-02-27
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2021-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02085070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02085070, "MK-3475 in Melanoma and NSCLC Patients With Brain Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02085070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*